Physician profile
Decarlo Noble
NPI 1073610002
$518.13
in general payments reported to CMS, 2019-2025
15 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.24 · 2020: $32.18 · 2021: $46.41 · 2022: $17.89 · 2023: $62.02 · 2024: $165 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $115.26 | 2024 | |
| Abbvie INC. | $69.38 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $53.65 | 2025 | Exparel |
| Biogen, INC. | $47.06 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $32.90 | 2019-2024 | |
| Exeltis, USA INC. | $32.67 | 2023-2024 | Slynd |
| Avion Pharmaceuticals | $31.72 | 2019 | |
| Mayne Pharma Commercial LLC | $29.14 | 2023 | |
| Astellas Pharma US INC | $18.91 | 2023 | Myrbetriq |
| Sage Therapeutics, LLC | $18.41 | 2025 | Zurzuvae |
| Organon LLC | $16.34 | 2025 | Nexplanon |
| Allergan, INC. | $15.59 | 2020 | |
| Molnlycke Health Care US, LLC | $13.86 | 2024 | Mepilex Border Post-Op Ag, Mepilex Border Post-Op, Avance |
| Amag Pharmaceuticals, INC. | $11.73 | 2019 | |
| Merck Sharp & Dohme LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Decarlo Noble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.